Search
for
Sort by
Research 841–870 of 1000+
- Case Series and Literature Review on Tofacitinib for Treating Severe Alopecia Areata
- Baricitinib in the Management of Severe Alopecia Areata: A Report of Two Cases With Sustained Clinical Response
- Hair Tonic Lotion with Cumaru Extract for Psoriasis Care: in vitro Development and Characterization
- Evidence for the off-label use of tofacitinib in alopecia areata
- Plant-based approaches in the management of polycystic ovary syndrome: A review
- Advances in dermatology research: A comprehensive literature review
- Baricitinib for the Treatment of Moderate-to-Severe Alopecia Areata
- Pentacyclic Triterpenoid Maslinic Acid Promotes Hair Growth Comparable to Minoxidil: A New Insight on the Potential Involvement of Cilia Activity
- Effects of local and systemic medications on eye health: Adverse reactions
- Emerging smart microneedle technologies in psoriasis: convergence of nanocarriers, machine learning, and personalized delivery
- Type-2 immunity associated with type-1 related skin inflammatory diseases: friend or foe?
- Efficacy of Janus kinase inhibitors in adult patients with alopecia areata
- Alopecia Areata in Underrepresented Groups: Preliminary Analysis of the All of Us Research Program
- Dermatomyositis Disease in Dogs
- Role of PRP (platelet-rich plasma) in alopecia areata: A literature review
- Efluvio anágeno. Hallazgos tricoscópicos
- Nutritional Management of Menopausal Women
- Efficacy of Betamethasone Oral Mini-Pulse Therapy in the Treatment of Lichen Planus
- Inflammasome Proteins as Biomarkers of Injury and Disease
- Cutaneous Lupus Erythematosus
- News in brief
- Lichen planopilaris
- TICE salvage chemotherapy treats germ-cell tumors effectively
- 13. Wound Healing & Hair
- 4. Bullous/Mucous Membrane
- WHAT OTHER JOURNALS ARE SAYING
- Psoriasis
- The zombie commodity: hair and the politics of its globalization
- Pathobiology questions raised by telogen effluvium and trichodynia in COVID‐19 patients
- RE: EFFECT OF THE DUAL 5α-REDUCTASE INHIBITOR DUTASTERIDE ON MARKERS OF TUMOR REGRESSION IN PROSTATE CANCER